Patient derived glioma stem cell spheroid reporter assays for live cell high content analysis.
3-dimensional
Cell cycle
Drug discovery
Glioblastoma
Spheroid
Journal
SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
06
08
2022
revised:
03
09
2022
accepted:
13
09
2022
pubmed:
19
9
2022
medline:
14
3
2023
entrez:
18
9
2022
Statut:
ppublish
Résumé
Three dimensional models of cell culture enables researchers to recreate aspects of tumour biology not replicated by traditional two dimensional techniques. Here we describe a protocol to enable automated high throughput phenotypic profiling across panels of patient derived glioma stem cell spheroid models. We demonstrate the use of both live/dead cell end-points and monitor the dynamic changes in the cell cycle using cell lines expressing the FUCCI cell cycle reporter. Together, these assays provide additional insight into the mechanism of action of compound treatments over traditional cell viability assay endpoints.
Identifiants
pubmed: 36116760
pii: S2472-5552(22)13694-4
doi: 10.1016/j.slasd.2022.09.002
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-19Subventions
Organisme : Cancer Research UK
ID : A29368
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A28596
Pays : United Kingdom
Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Neil Carragher reports financial support was provided by Cancer Research UK. Neil Carragher reports financial support was provided by Brain Tumour Charity. Neil Carragher reports a relationship with Cancer Research UK that includes: funding grants and travel reimbursement.